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SUMMARY
The aim of this study was to investigate whether there is an impact of
donation rates on the quality of lungs used for transplantation and
whether donor lung quality affects post-transplant outcome in the current
Lung Allocation Score era. All consecutive adult LTx performed in Euro-
transplant (ET) between January 2012 and December 2016 were included
(N = 3053). Donors used for LTx in countries with high donation rate
were younger (42% vs. 33% ≤45 years, P < 0.0001), were less often smok-
ers (35% vs. 46%, P < 0.0001), had more often clear chest X-rays (82% vs.
72%, P < 0.0001), had better donor oxygenation ratios (20% vs. 26% with
PaO2/FiO2 ≤ 300 mmHg, P < 0.0001), and had better lung donor score
values (LDS; 28% vs. 17% with LDS = 6, P < 0.0001) compared with
donors used for LTx in countries with low donation rate. Survival rates for
the groups LDS = 6 and ≥7 at 5 years were 69.7% and 60.9% (P = 0.007).
Lung donor quality significantly impacts on long-term patient survival.
Countries with a low donation rate are more oriented to using donor
lungs with a lesser quality compared to countries with a high donation
rate. Instead of further stretching donor eligibility criteria, the full potential
of the donor pool should be realized.
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Introduction
Early and late survival have improved over the last dec-
ades leading to an extension of listing indications. As a
result, referral for lung transplantation increased such
that the number of patients on the lung transplant wait-
ing list outpaced the availability of donor organs. In
2018, 1036 patients were on the lung transplant waiting
list in Eurotransplant at year-end, while 719 had
received a lung transplant and 137 patients died await-
ing an organ offer [1].
Worldwide, only 20–30% of organ donors become
lung donors [2,3]. The dramatic organ shortage encour-
ages centers to expand lung donor suitability criteria in
order to maximize recovery and usage rate of every
reported lung donor. Lung donor yield can be improved
by increased utilization of extended-criteria donors.
This percentage of used extended-criteria donors varies
widely across centers ranging from 24% to 77% of the
total transplant volume [2].
Out of the eight countries that collaborate within
Eurotransplant, four had active lung transplant pro-
grams in the study period. These four countries have
different donor legislative frameworks: Austria and Bel-
gium use an opting-out system, where every citizen is
considered an organ donor unless an active registration
against donation has taken place. Germany and the
Netherlands apply an opting-in system which requires
an active registration in order to be considered as
organ donor. As a consequence, the number of lung
donors used for transplantation per million population
was in 2018 for Austria: 9.8; for Belgium: 10.8; for
Germany: 3.8; and for the Netherlands: 4.7 (Fig. 1).
Furthermore, waiting list mortality rates in countries
with low donation rates (Germany and the Nether-
lands) are higher compared to those in countries with
high donation rates (Austria and Belgium): 12% vs.
7% at 1 year [1].
Because of the large discrepancies among the Euro-
transplant countries, Dutch members of parliament
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Figure 1 Donation rates per million population of used diseased donor lungs, by year, by donor country.
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have asked for a change in legislation. The proposal
for change toward an opting-out scheme was success-
fully passed in 2018, and the new organ donor law
will be implemented July 1, 2020 [4]. Parliamentary
discussions in Germany have just started, and the
authors hope that with additional insight gained by
the current study, Germany will, as the last country
in Eurotransplant, also adopt the opting-out system.
In May 2005, the Lung Allocation Score (LAS) was
implemented in the United States. This allocation sys-
tem replaced a scheme based solely on waiting time.
There were three objectives: reduce the number of
deaths on the lung transplant waiting list; increase the
survival benefit for lung recipients; and ensure the
efficient and equitable allocation of lungs to transplant
candidates [5]. Germany was the first country to
adopt the LAS as national allocation policy on Decem-
ber 10, 2011; the Netherlands followed on April 22,
2014 [6].
The aim of this study was to investigate whether
there is an impact of donation rates on the quality of
lungs used for transplantation and whether donor lung
quality affects post-transplant outcome in the current
LAS era.
Patients and methods
Definitions
The lung donor score (LDS) is a Eurotransplant adap-
tation of the Oto score [7,8], where the ideal donor has
a LDS value of 6. This LDS is an instrument to gauge
donor quality based on six preprocurement variables:
general and smoking history, age, arterial blood gases,
chest X-ray, and bronchoscopic findings (Table 1). The
LDS of six points is equivalent to the ISHLT definition
of standard donor lung with the exception that chest
X-ray images showing edema or atelectasis, bron-
choscopy findings of nonpurulent secretions, and PaO2/
FiO2 measurements between 300 and 350 mmHg do
not increase the score [9]. The lung donor score’s vari-
ables are registered electronically in Eurotransplant as
of 2002.
Patients were classified into four groups depending
on their underlying disease: Group A, obstructive airway
diseases (e.g., chronic obstructive pulmonary disease
[COPD]); Group B, diseases of the pulmonary circula-
tion (e.g., idiopathic pulmonary arterial hypertension);
Group C, suppurative lung diseases (e.g., cystic fibrosis
[CF]); and Group D, restrictive lung diseases (e.g., pul-
monary fibrosis).
Throughout the manuscript Austria and Belgium
were labeled as “high donation rate” countries and Ger-
many and the Netherlands as “low donation rate” coun-
tries.
Lung Allocation Score
The LAS is a numerical value used to assign relative pri-
ority in distributing donated lungs. The LAS evaluates
several parameters of patient health to direct organ
donation toward patients obtaining greatest benefit
from lung transplantation. The score is calculated from
objective clinical measures of the patient’s current
health status to estimate survival probability and pro-
jected duration of 1-year survival with or without a
lung transplant. LAS values range from 0 to 100, with
Table 1. The Eurotransplant lung donor score.
Factor Points
Donor age (year)
<45 1
45–54 1
55–59 2
60+ 3
Donor history
Compromised* 4
Uncompromised 1
Smoking history
Yes 2
No 1
NA 1
Chest X-ray
Clear 1
Edema 1
Shadow 2
Atelectasis 1
Consolidation 2
NA 1
Bronchoscopy
Clear 1
Non purulent 1
Purulent 2
Inflammation 3
Visualized tumor 5
NA 1
PO2/FiO2 (mmHg)
>450 1
351–450 1
301–350 2
≤300 3
NA 2
*The donor history is compromised in case of a malignancy,
sepsis, drug abuse, meningitis, or a positive virology (HBsAg,
HBcAb, and HCVAb) was registered.
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Table 2. Demographic statistics.
ALL
Transplant country
P-valueAustria/Belgium Germany/Netherlands
Total 3053 1118 1935
Recipient
Age (years)
<45 764 (25%) 300 (27%) 464 (24%) <0.0001
45–54 718 (24%) 217 (20%) 501 (26%)
55–59 713 (23%) 261 (23%) 452 (23%)
≥60 858 (28%) 340 (30%) 518 (27%)
Diagnosis group
Obstructive (Group A) 1302 (43%) 574 (51%) 728 (38%) <0.0001
Vascular (Group B) 136 (4%) 74 (7%) 62 (3%)
Infectious (Group C) 484 (16%) 159 (14%) 325 (17%)
Restrictive (Group D) 965 (32%) 269 (24%) 696 (36%)
Other 166 (5%) 42 (4%) 124 (6%)
LAS
1–30 104 (4%) 100 (13%) 4 (0%) <0.0001*
30–34 865 (33%) 313 (43%) 552 (30%)
35–39 501 (19%) 101 (14%) 400 (21%)
40–49 535 (21%) 90 (12%) 445 (24%)
50+ 593 (23%) 128 (18%) 465 (25%)
Missing 455 386 69
BMI (median IQR) 22 (19–26) 22 (19–25) 23 (20–26) <0.0001
Donor
Age (years)
<45 1119 (37%) 467 (42%) 652 (33%) <0.0001
45–54 887 (29%) 315 (28%) 572 (30%)
55–59 405 (13%) 150 (13%) 255 (13%)
≥60 642 (21%) 186 (17%) 456 (24%)
Smoking history
Yes 1149 (42%) 334 (35%) 815 (46%) <0.0001*
No 1594 (56%) 622 (65%) 972 (54%)
Missing 310 162 148
Bronchoscopy
Clear 1707 (86%) 304 (88%) 1403 (85%) 0.38*
Non purulent 77 (3%) 8 (2%) 69 (4%)
Purulent 134 (7%) 22 (6%) 112 (7%)
Inflammation 70 (4%) 11 (4%) 59 (4%)
NA 1065 773 292
Chest X-ray
Clear 2050 (75%) 766 (82%) 1284 (72%) <0.0001*
Edema 244 (9%) 53 (6%) 191 (11%)
Shadow 83 (3%) 19 (2%) 64 (4%)
Atelectasis 156 (6%) 45 (5%) 111 (6%)
Consolidation 179 (7%) 53 (5%) 126 (7%)
NA 341 182 159
Donor history
Compromised 134 (4%) 35 (3%) 99 (5%) 0.010
Uncompromised 2919 (96%) 1083 (97%) 1836 (95%)
PaO2/FiO2 (mmHg)
≤300 716 (24%) 222 (20%) 494 (26%) <0.0001
301–350 369 (12%) 114 (10%) 255 (13%)
351–450 926 (30%) 327 (29%) 599 (31%)
>450 942 (31%) 419 (38%) 523 (27%)
NA 100 (3%) 36 (3%) 64 (3%)
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higher scores indicative of greater predicted survival
benefit, directing priority toward these patients, and
hence excluding wait list time [10]. Although eight
countries collaborate in Eurotransplant, in this study
period only four countries (Austria, Belgium, Germany,
and the Netherlands) had active lung transplant pro-
grams. Germany and the Netherlands use the LAS scor-
ing system for their national allocation while all 4
countries use the LAS scoring system for international
donor lung exchange since December 10, 2011.
Study design
Historical prospective study including all adult
(≥16 years) consecutive lung-only transplant recipients
in the Eurotransplant area between January 1, 2012, and
December 31, 2016.
Statistical analysis
Continuous variables were analyzed using the Wil-
coxon–Mann–Whitney test, while chi-square statistics
were used to compare categorical variables. Survival
rates were examined with time-to-event analysis in
which the event was defined as patient death. Patients
were followed up until December 31, 2018. Univariable
survival analyses were performed by Kaplan–Meier
method. Survival rates were compared using the log-
rank test. Multivariable analysis was performed with
Cox’s proportional hazards model and included the fol-
lowing factors: recipient primary diagnosis, recipient
age, LAS at transplant, lung donor score, DCD/DBD
donor, and transplant country. Missing data were
included in the LDS model as a “non available” class.
All analyses were performed using SAS statistical pro-
gram version 9.1 (SAS Institute, Indianapolis, IN, USA).
A P-value below 0.05 was considered statistically signifi-
cant.
Results
Demographics
The study population included 3053 lung transplants, of
which 1118 (37%) were performed in Austria and Bel-
gium (A/B) and 1935 (63%) in Germany and the
Netherlands (G/N; Table 2).
Compared with Germany and the Netherlands,
patients transplanted in Austria and Belgium were more
often aged <45 years (27% vs. 24%) and more often
aged ≥60 years (30% vs. 27%, P < 0.0001). Their pri-
mary diagnosis was more often Obstructive (51% vs.
38%) and less often Restrictive (24% vs. 36%,
P < 0.0001). Patients transplanted in A/B were less
often transplanted with a high LAS value (18% vs. 25%
with LAS ≥50, P < 0.0001), compared with patients
transplanted in G/N. Lung donors used for transplanta-
tion in A/B were younger (42% vs. 33% in age class
≤45 years, P < 0.0001), were less often smokers (35%
vs. 46%, P < 0.0001), had more often a clear chest X-
ray (82% vs. 72%, P < 0.0001), had less often a com-
promised donor history (3% vs. 5%, P = 0.010), had
better donor oxygenation ratio [partial arterial pressure
of oxygen (PaO2)/fraction of inspired oxygen (FiO2);
Table 2. Continued.
ALL
Transplant country
P-valueAustria/Belgium Germany/Netherlands
LDS
6 638 (21%) 317 (28%) 321 (17%) <0.0001
≥7 2415 (79%) 801 (72%) 1614 (83%)
Donor type
DCD† 272 (9%) 125 (11%) 147 (8%) 0.001
DBD 2781 (81%) 993 (89%) 1788 (92%)
Transplantation
Single lung 287 38 (3%) 249 (13%) <0.0001
Double lung 2766 1080 (97%) 1696 (87%)
Cold ischemia time (h)
Median (IQR) 6 (5.5–6.4) 6 (5.2–6.0) 6 (5.7–7.1) 0.37
*P-value without NA/missing class.
†DCD donation and transplantation is legally not allowed in Germany.
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20% vs. 26% with PaO2/FiO2 ≤ 300 mmHg,
P < 0.0001], and had better LDS values (28% vs. 17%
with LDS = 6, P < 0.0001).
Six transplant centers were active in the high dona-
tion rate countries; the annual transplant volume was
as follows: 1–4 LTx: 1 center; 10–19 LTx: 2 centers;
20–29 LTx: 1 center; and 50+ LTx: 2 centers. In the
low donation rate countries, 18 centers had an active
LTx program with the following annual transplant vol-
ume: 1–4 LTx: 2 centers; 5–9 LTx: 5 centers; 10–19
LTx: 7 centers; 30–39 LTx: 2 centers; and 50+ LTx: 2
centers.
Donor quality over time
The distribution of the LDS among patients trans-
planted in the period 2002–2018 is shown in Fig. 2. In
the years 2003, 2008, 2012, and 2017, the proportion of
patients transplanted with a lung with LDS of 6
decreased from 44% to 31% to 22% to 17%.
Donor age distribution since the start of the first lung
transplant is shown in Fig. 3. All other components of
the LDS are systematically recorded since 2002 and rep-
resented in Fig. 4a–d. In the most recent decades, the
usage of older donors, donors with a smoking history,
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Figure 2 Proportion of lung-only transplants by lung donor score over time.
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Figure 3 Proportion of lung-only transplants by donor age over time.
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Figure 4 (a) Proportion of lung-only
transplants by donor X-ray classes
over time. (b) Proportion of lung-only
transplants by donor bronchoscopy
classes over time. (c) Proportion of
lung-only transplants by donor PaO2/
FiO2 classes over time. (d) Proportion
of lung-only transplants by donor
smoking status over time.
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donors without a clear chest X-ray, and donors with a
low PaO2/FiO2 ratio has increased compared with the
earlier transplants.
Post-transplant survival
The survival rates for the groups LDS = 6 and LDS ≥7 at
1, 2, and 5 years were 85.9%, 79.3%, and 69.7% and
82.9%, 76.1%, and 60.9%, respectively (P = 0.007; Fig. 5).
Factors associated with overall patient survival
Table 3 shows the unadjusted and adjusted hazard rates
on post-transplant survival.
The unadjusted HR for the factor that represents the
transplant countries is 1.18 (95% CI 1.02–1.35)
P = 0.029 and the 5-year survival rates are 66.7% for
the high donation rate countries (A/B) and 60.8% for
the low donation rate countries (G/N; P = 0.001). In
the multivariable model, the effect of the factor “Trans-
plant Country” on survival is no longer observed [HR:
0.90 (95% CI 0.74–1.10) P = 0.30].
Unadjusted survival rates in low donation rate coun-
tries were lower compared to high donation rate coun-
tries with 5-year survival rates at 60.8% and 66.7% for
low and high donation rate countries, respectively
(P = 0.001). However when corrected for confounding
factors, like the LDS, this country effect disappeared.
This observation implies that part of the country effect
can be explained by the difference in the quality of
organs used for transplantation.
The multivariable model showed that the factors
transplant volume, type of lung transplant (double vs.
single), duration of cold ischemia time, primary diag-
nosis, LAS value at transplantation, and the lung donor
score [HR: 1.35 (95% CI: 1.13–1.61), P = 0.001] were
found to be independent predictors of survival
(Table 3).
Discussion
The Oto LDS was the first attempt at quantifying over-
all donor lung quality [7,8,11]. Eurotransplant’s adapta-
tion of this score has been shown to be associated with
donor usage. Reported donor lungs which in reality
were judged to be unsuitable for transplantation and
hence discarded were those with a higher LDS at time
of reporting. In addition, post-transplant recipient out-
come of donors with a higher LDS was found to be sig-
nificantly worse compared to transplants performed
with better quality lungs.
In the last 15 years, donor quality of the transplanted
lungs, as measured by the LDS has decreased: in 2003,
44% of all donors were ideal donors with a LDS of 6,
and in 2017 this proportion dropped to 17%. This
reduction in quality of used donor lungs can be attribu-
ted to the increase in donor age, to the increase of the
usage of donors with a smoking history, donors without
a clear chest X-ray, and donors with a lower PaO2/FiO2
ratio.
The observed decline in lung allograft quality raises
the question of its impact on outcome. Our data show
that lung recipients from donors with a LDS ≥7 had a
significantly jeopardized long-term outcome compared
to those with an optimal lung quality: 69.7% and 60.9%
for LDS = 6 and ≥7 at 5 years, respectively (P = 0.007).
A considerable number of studies are published showing
no disadvantage when extended-criteria donor lungs
were used [3,12–14]. Liberalization of donor criteria
and retaining optimal patient outcome is also a result
of increased experience and might explain these discrep-
ancies.
Our study hypothesis was that there is an impact of
donation rates on the quality of lungs used for trans-
plantation; this hypothesis was confirmed by our data:
lung donors used for transplantation in countries with a
high donation rate were younger, were less often smok-
ers, had more often a clear chest X-ray, less often a
compromised donor history, had a better donor oxy-
genation, and had a lower LDS compared with donors
Figure 5 Post-transplant survival by lung donor score [LDS = 6
(N = 638) dark blue line and LDS ≥7 (N = 2415) light green line].
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used for transplantation in countries with a low dona-
tion rate.
Doctors are trained to solve problems, not to create
them. Hence, faced with an organ shortage lung donor
suitability criteria become wider in order to maximize
recovery and usage rate of every reported lung donor.
But should these criteria be further stretched if the
national lung donation rate is half that of other coun-
tries?
Optimally exploiting the potential of deceased organ
donation could substantially increase the donor pool.
Roels et al. showed that more than 57% of deceased
potential donors were missed along the donation
pathway because of nonidentification, no referral, no
approach of relatives, or objections to donate. In coun-
tries with lower donation rates, expectedly more poten-
tial donors are missed proportionally [15]. Efforts to
increase the organ pool should therefore focus on opti-
mizing clinical practices in deceased organ donation in
addition to installing an opting-out system.
Ex vivo lung perfusion has recently emerged as a new
technology to safely prolong cross-clamp time for stan-
dard-criteria donor lungs [16,17] and to re-evaluate
questionable lungs from extended-criteria donors such
as older donor lungs, DCD lungs, lungs with low oxy-
genation capacity, and lungs with expected long cold
Table 3. Univariate and multivariate analysis of post-transplant survival.
Factor N Unadj HR (95% CI) P-value Adj HR 95% CI P-value
Recipient age (years)
<45 764 1 <0.0001 1 0.12
45–54 718 1.03 (0.84–1.26) 0.96 0.75–1.23
55–59 713 1.25 (1.02–1.52) 1.14 0.89–1.46
≥60 858 1.46 (1.22–1.76) 1.20 0.94–1.53
Diagnosis
Obstructive 1302 1 <0.0001 1 0.009
Vascular 136 1.22 (0.88–1.69) 1.53 1.08–2.17
Infectious 484 0.88 (0.71–1.09) 1.01 0.77–1.34
Restrictive 965 1.40 (1.20–1.63) 1.26 1.06–1.50
Other 166 1.29 (0.96–1.73) 1.36 0.99–1.86
LAS
<50 2005 1 <0.0001 1 <0.0001
≥50 593 1.81 (1.56–2.11) 1.60 1.35–1.88
0 455 1.05 (0.85–1.28) 1.26 0.90–1.41
BMI 1.004 (0.99–1.01) 0.24 1 0.99–1.01 0.97
LDS
6 638 1 0.006 1 0.001
≥7 2415 1.27 (1.07–1.52) 1.35 1.13–1.61
Donor type
DBD 2781 1 0.032 1 0.10
DCD 272 0.75 (0.57–0.98) 0.79 0.59–1.05
Transplant country
A/B 1118 1 0.029 1 0.30
G/N 1935 1.18 (1.02–1.35) 0.90 0.74–1.10
Transplant volume (number/year)
50+ 1661 1 <0.0001 1 <0.0001
1–4 35 3.11 (1.94–5.00) 4.40 2.71–7.12
5–9 173 2.34 (1.84–2.98) 2.83 2.18–3.69
10–19 744 1.67 (1.42–1.95) 1.69 1.42–2.01
20–29 135 2.19 (1.67–2.87) 3.15 2.30–4.31
30–39 305 1.11 (0.86–1.43) 1.09 0.82–1.45
Type of LTx
Double 2766 1 <0.0001 1 <0.0001
Single 287 2.14 (1.78–2.57) 1.90 1.57–2.31
Cold ischemic
<6 896 1 0.001 1 <0.0001
Time (h)
≥6 2157 1.30 (1.12–1.51) 1.76 1.48–2.08
Transplant International 2020; 9
ª 2020 Eurotransplant International Foundation. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
Donor lung quality and survival in the LAS era
ischemic times [18]. These strategies may help to
increase the donor pool in the future in countries with
lower organ donation rates. However, the concept of
using DCD lungs is not legally allowed in Germany,
which is the country in Eurotransplant with the largest
number of potential donors, but with the lowest num-
ber of actual donors per inhabitants. Some of the lung
transplant centers in Eurotransplant have now started
using EVLP as a tool to reassess donor lungs of inferior
quality. However, the impact on increasing the actual
donor pool in the individual ET countries remains
unknown and could not be examined in the present
study.
There are various strategies to increase the donor
pool; these include legislative action, public campaigns,
in-hospital training programs, extending the selection
criteria for lung donors, and using from lungs from
donors who died after circulatory arrest (DCD) [2]. A
study from the ISHLT DCD registry showed that out-
comes of DCD were similar to DBD [19]. This is con-
firmed in our cohort: [HR: 0.79 (95% CI: 0.59–1.05),
P = 0.10]. In several Eurotransplant countries, there are
still legal barriers that preclude DCD donation as is
now the case in Germany. Removing these barriers
could further expand the lung donor pool by 20%,
which might lower the usage of lung donors with a high
LDS [20,21].
It has been advocated and shown that increasing
organ donation rates can be achieved by introducing
presumed consent legislation [22,23]. But presumed
consent alone cannot explain all the variation in organ
donation rates between different countries [24], and
opting-out systems have also been shown not to
increase donation rates on its own [25,26]. Establishing
an optimal legal framework should be aided by public
support, public trust, and the role of the family in
donation decisions [27].
This study has several limitations inherent to a multi-
center registry. Although Eurotransplant collects a
robust set of donor variables on a large number of
records, data are missing, but these missing values are
modeled and reported as such. No information on pri-
mary graft dysfunction nor on chronic rejection is avail-
able. As with any observational study, associations may
not be causal. The center experience in assessing donor
quality, reconditioning of donor lungs with EVLP,
selecting suitable candidates, and excelling in the prac-
tice of using nonideal donors is not modeled and con-
stitutes a serious bias in this analysis.
Our data show that donor lung quality impacts on
long-term patient survival and that higher quality donor
lungs are more often used for transplantation in coun-
tries with a high donation rate compared to countries
with a low donation rate. In the quest for finding more
suitable organs, first the full potential of the donor pool
should be realized. Professionals working in countries
with a low donation rate should make every effort to
convince policy makers to change their current national
donor legislation by introducing opting-out as well as
DCD legislation.
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